COSCIENS Biopharma Inc. (LON:0UGB)

COSCIENS Biopharma Statistics

Total Valuation

LON:0UGB has a market cap or net worth of GBP 4.70 million. The enterprise value is -68,130.

Market Cap	4.70M
Enterprise Value	-68,130

Important Dates

The next estimated earnings date is Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	3.25M
Shares Outstanding	n/a
Shares Change (YoY)	+30.54%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	0.55%
Owned by Institutions (%)	0.00%
Float	2.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.70
PB Ratio	1.24
P/TBV Ratio	1.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.01
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.01

Financial Position

The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.43.

Current Ratio	3.47
Quick Ratio	2.54
Debt / Equity	0.43
Debt / EBITDA	n/a
Debt / FCF	-0.20
Interest Coverage	-47.69

Financial Efficiency

Return on equity (ROE) is -118.80% and return on invested capital (ROIC) is -131.40%.

Return on Equity (ROE)	-118.80%
Return on Assets (ROA)	-14.01%
Return on Invested Capital (ROIC)	-131.40%
Return on Capital Employed (ROCE)	-38.15%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	168,391
Profits Per Employee	-277,229
Employee Count	40
Asset Turnover	0.27
Inventory Turnover	1.99

Taxes

In the past 12 months, LON:0UGB has paid 804,943 in taxes.

Income Tax	804,943
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.21% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-32.21%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	30.87
Average Volume (20 Days)	195

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LON:0UGB had revenue of GBP 6.74 million and -11.09 million in losses. Loss per share was -3.52.

Revenue	6.74M
Gross Profit	2.98M
Operating Income	-5.64M
Pretax Income	-10.28M
Net Income	-11.09M
EBITDA	-4.94M
EBIT	-5.64M
Loss Per Share	-3.52

Balance Sheet

The company has 6.34 million in cash and 1.62 million in debt, with a net cash position of 4.73 million.

Cash & Cash Equivalents	6.34M
Total Debt	1.62M
Net Cash	4.73M
Net Cash Per Share	n/a
Equity (Book Value)	3.78M
Book Value Per Share	1.19
Working Capital	7.33M

Cash Flow

In the last 12 months, operating cash flow was -7.44 million and capital expenditures -720,878, giving a free cash flow of -8.16 million.

Operating Cash Flow	-7.44M
Capital Expenditures	-720,878
Free Cash Flow	-8.16M
FCF Per Share	n/a

Margins

Gross margin is 44.30%, with operating and profit margins of -83.74% and -164.63%.

Gross Margin	44.30%
Operating Margin	-83.74%
Pretax Margin	-152.68%
Profit Margin	-164.63%
EBITDA Margin	-73.27%
EBIT Margin	-83.74%
FCF Margin	n/a

Dividends & Yields

LON:0UGB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.54%
Shareholder Yield	-30.54%
Earnings Yield	-235.72%
FCF Yield	-173.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 21, 2022. It was a reverse split with a ratio of 0.04.

Last Split Date	Jul 21, 2022
Split Type	Reverse
Split Ratio	0.04

Scores

LON:0UGB has an Altman Z-Score of -1 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1
Piotroski F-Score	4